Abemaciclib: observed
36 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingNCT07856225Report a problem
- Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast CancerRecruitingNCT07531693Report a problem
- Real-world Studies of CDK4/6 InhibitorsRecruitingNCT07407439Report a problem
- Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without DiarrheaRecruitingNCT07264998Report a problem
- Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.RecruitingNCT07243002Report a problem
- Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast CancerRecruitingNCT07180056Report a problem
- Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer PatientsRecruitingNCT07151911Report a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
- A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceRecruitingNCT06830720Report a problem
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyRecruitingNCT06805812Report a problem
- Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast CancerRecruitingNCT06650423Report a problem
- Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)RecruitingNCT06621459Report a problem
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsRecruitingNCT06388122Report a problem
- A Retrospective Real-world Study of Abemaciclib in HR+ Breast CancerNot yet recruitingNCT06341283Report a problem
- A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 InhibitorsRecruitingNCT06171360Report a problem
- A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among BreastNot yet recruitingNCT05267327Report a problem
- Real-world Data in Patients With Breast Cancer Treated With AbemaciclibRecruitingNCT04985058Report a problem
- To Identify Primary Resistance to CDK4/6 Inhibitors in Breast CancerRecruitingNCT04660435Report a problem
- A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 InhibitorsCompletedNCT07647042Report a problem
- A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 InhibitorsCompletedNCT07512063Report a problem
- Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)WithdrawnNCT07475923Report a problem
- Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records DatabasesCompletedNCT07225790Report a problem
- Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in PortugalCompletedNCT07223476Report a problem
- Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) StudyActive, not recruitingNCT07008508Report a problem
- A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerActive, not recruitingNCT06495164Report a problem
- Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast CancerCompletedNCT06367335Report a problem
- Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast CancerActive, not recruitingNCT06344780Report a problem
- Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.TerminatedNCT06126003Report a problem
- Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.CompletedNCT05789771Report a problem
- Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 InhibitorsCompletedNCT05153135Report a problem
- A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 InhibitorsCompletedNCT05141240Report a problem
- Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownNCT04852081Report a problem
- Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer PatientsCompletedNCT04681768Report a problem
- Implementing Patients´ Competence in Oral Breast Cancer TherapyStatus unknownNCT04030728Report a problem
- Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerApproved for marketingNCT03763604Report a problem
- Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerApproved for marketingNCT02792725Report a problem